For a long time, the strategy has been to engage a partner for INV103 off the back of the recently released trial results and this would fund the development of the respiratory portfolio without contributing to further dilution.
The question is whether negotiations with a potential partner is able to be completed before we require more cash...
Would i be correct in assuming that the cash expenditure would be significantly reduced following the completion of the 2 (INV102/103) trials?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $10.59M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.5¢ | 12.5¢ | $15.62K | 118.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 213400 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 57707 | 2 |
View Market Depth
| Last trade - 14.46pm 20/06/2025 (20 minute delay) ? |
| IVX (ASX) Chart |